Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2016

01-11-2016 | Breast Oncology

The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis

Published in: Annals of Surgical Oncology | Issue 12/2016

Login to get access

Abstract

Purpose

There is no consensus on adequate negative margins in breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS). We systematically reviewed the evidence on margins in BCS for DCIS.

Methods

A study-level meta-analysis of local recurrence (LR), microscopic margin status and threshold distance for negative margins. LR proportion was modeled using random-effects logistic meta-regression (frequentist) and network meta-analysis (Bayesian) that allows for multiple margin distances per study, adjusting for follow-up time.

Results

Based on 20 studies (LR: 865 of 7883), odds of LR were associated with margin status [logistic: odds ratio (OR) 0.53 for negative vs. positive/close (p < 0.001); network: OR 0.45 for negative vs. positive]. In logistic meta-regression, relative to >0 or 1 mm, ORs for 2 mm (0.51), 3 or 5 mm (0.42) and 10 mm (0.60) showed comparable significant reductions in the odds of LR. In the network analysis, ORs relative to positive margins for 2 (0.32), 3 (0.30) and 10 mm (0.32) showed similar reductions in the odds of LR that were greater than for >0 or 1 mm (0.45). There was weak evidence of lower odds at 2 mm compared with >0 or 1 mm [relative OR (ROR) 0.72, 95 % credible interval (CrI) 0.47–1.08], and no evidence of a difference between 2 and 10 mm (ROR 0.99, 95 % CrI 0.61–1.64). Adjustment for covariates, and analyses based only on studies using whole-breast radiotherapy, did not change the findings.

Conclusion

Negative margins in BCS for DCIS reduce the odds of LR; however, minimum margin distances above 2 mm are not significantly associated with further reduced odds of LR in women receiving radiation.
Appendix
Available only for authorised users
Literature
1.
Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8.CrossRefPubMed
2.
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.CrossRefPubMedPubMedCentral
3.
Irwig L, Bennetts A. Quality of life after breast conservation or mastectomy: a systematic review. Aust N J Surg. 1997;67:750–54.CrossRef
4.
Wang S-Y, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst. 2012;104:507–16.CrossRefPubMedPubMedCentral
5.
Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–20.CrossRefPubMed
6.
Pilewskie M, Morrow M. Extent and role of margin control for DCIS managed by breast-conserving surgery. In: Newman LA, Bensenhaver JM, editors. Ductal carcinoma in situ and microinvasive/borderline breast cancer. New York: Springer; 2015. pp. 67–83.CrossRef
7.
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507–15.CrossRefPubMed
8.
9.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology, breast cancer version 1. 2016. http://​www.​nccn.​org. Accessed 14 Dec 2015.
10.
11.
New Zealand Guidelines Group (NZGG). Ductal carcinoma in situ. Management of early breast cancer: evidence-based best practice guideline. Wellington: New Zealand Guidelines Group; 2015. pp. 133–41.
12.
Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30.CrossRefPubMed
13.
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology—American Society for Radiation Oncology—American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Ann Surg Oncol. 2016. doi:10.​1245/​s10434-016-5449-z.
14.
Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in situ of the breast: a critical review of the literature. J Clin Oncol. 2002;20:2736–44.CrossRefPubMed
15.
Kong I, Narod SA, Taylor C, et al. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol. 2014;21:e96–104.CrossRefPubMedPubMedCentral
16.
Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21:717–30.CrossRefPubMed
17.
Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46:3219–32.CrossRefPubMed
18.
Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons mammosite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011;79:808–17.CrossRefPubMed
19.
Hathout L, Hijal T, Theberge V, et al. Hypofractionated radiation therapy for breast ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2013;87:1058–63.CrossRefPubMed
20.
Ben-David MA, Sturtz DE, Griffith KA, et al. Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: The University of Michigan experience. Breast J. 2007;13:392–400.CrossRefPubMed
21.
Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137–46.CrossRefPubMed
22.
Rodrigues N, Carter D, Dillon D, Parisot N, Choi DH, Haffty BG. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:1331–5.CrossRefPubMed
23.
Cutuli B, Cohen-Solal-Le NC, De LB, et al. Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer. 2001;37:2365–72.CrossRefPubMed
24.
Hiramatsu H, Bornstein BA, Recht A, et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am. 1995;1:55–61.PubMed
25.
Cataliotti L, Distante V, Ciatto S, et al. Intraductal breast cancer: review of 183 consecutive cases. Eur J Cancer. 1992;28:917–20.CrossRef
26.
Turaka A, Freedman GM, Li T, et al. Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol. 2009;100:25–31.CrossRefPubMedPubMedCentral
27.
Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262:623–31.PubMedPubMedCentral
28.
Meattini I, Livi L, Franceschini D, et al. Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 patients. Eur J Surg Oncol. 2013;39:613–8.CrossRefPubMed
29.
Chuwa EWL, Tan VHS, Tan P-H, Yong W-S, Ho G-H, Wong C-Y. Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors. ANZ J Surg. 2008;78:42–8.CrossRefPubMed
30.
MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys prognostic index for ductal carcinoma in situ. Cancer. 2007;110:2648–53.CrossRefPubMed
31.
Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853. A study by the EORTC breast cancer cooperative group and EORTC radiotherapy group. J Clin Oncol. 2006;24:3381–7.CrossRefPubMed
32.
Chasle J, Delozier T, Denoux Y, Marnay J, Michels J-J. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas: a preliminary study. Eur J Cancer. 2003;39:1363–9.CrossRefPubMed
33.
Nakamura S, Woo C, Silberman H, Streeter J, Lewinsky BS, Silverstein MJ. Breast-conserving therapy for ductal carcinoma in situ: A 20 year experience with excision plus radiation therapy. Am J Surg. 2002;184:403–9.CrossRefPubMed
34.
Neuschatz AC, DiPetrillo T, Safaii H, Lowther D, Landa M, Wazer DE. Margin width as a determinant of local control with and without radiation therapy for ductal carcinoma in situ (DCIS) of the breast. Int J Cancer. 2001;96:97–104.CrossRefPubMed
35.
Fowble B, Hanlon AL, Fein DA, et al. Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys. 1997;38:949–57.CrossRefPubMed
36.
Sweldens C, Peeters S, Van LE, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J. 2014;20:1–7.CrossRefPubMed
37.
Kim H, Noh JM, Choi DH, et al. Excision alone for small size ductal carcinoma in situ of the breast. Breast. 2014;23:586–90.CrossRefPubMed
38.
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105–24.CrossRefPubMed
39.
Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014;17:157–73.CrossRefPubMed
40.
Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of protocol b-17: intraductal carcinoma. Cancer. 1999;86:429–38.CrossRefPubMed
41.
Fish EB, Chapman J-A, Miller NA, et al. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast. Ann Surg Oncol. 1998;5:724–32.CrossRefPubMed
42.
Sahoo S, Recant WM, Jaskowiak N, Tong L, Heimann R. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience. Breast J. 2005;11:242–7.CrossRefPubMed
43.
Macdonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg. 2005;190:521–5.CrossRefPubMed
44.
Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;162–77.
45.
Cutuli B, Cohen-Solal-Le NC, De LB, et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience. Int J Radiat Oncol Biol Phys. 2002;53:868–79.CrossRefPubMed
46.
Tunon-De-Lara C, De-Mascarel I, Mac-Grogan G, et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment. The experience of one institute. Am J Clin Oncol Cancer Clin Trials. 2001;24:531–36.
47.
Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–18.CrossRefPubMed
48.
Chan KC, Fiona KW, Sinha G, et al. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer. 2001;91:9–16.CrossRefPubMed
49.
Warneke J, Grossklaus D, Davis J, et al. Influence of local treatment on the recurrence rate of ductal carcinoma in situ. J Am Coll Surg. 1995;180:683–8.PubMed
50.
Kestin LL, Goldstein NS, Martinez AA, et al. Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy. Patterns of failure and 10 year results. Ann Surg. 2000;231:235–45.CrossRefPubMedPubMedCentral
51.
Ringberg A, Idvall I, Ferno M, et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol. 2000;26:444–51.CrossRefPubMed
52.
Rudloff U, Brogi E, Reiner AS, et al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010;251:583–91.CrossRefPubMed
53.
Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences (with discussion). Stat Sci. 1992;7:457–511.CrossRef
54.
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B. 2002;64:583–639.CrossRef
Metadata
Title
The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis
Publication date
01-11-2016
Published in
Annals of Surgical Oncology / Issue 12/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5446-2

Other articles of this Issue 12/2016

Annals of Surgical Oncology 12/2016 Go to the issue

Gastrointestinal Oncology

Advances in Imaging and Endoluminal Therapies for Early Esophageal and Gastric Cancers

Gastrointestinal Oncology

What’s the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer

Gastrointestinal Oncology

The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients

Endocrine Tumors

Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden: Is the Benefit Worth the Risk?

Endocrine Tumors

Comparison of Learning Curves for Retroauricular and Transaxillary Endoscopic Hemithyroidectomy

Colorectal Cancer

Short Chemotherapy-Free Interval Improves Oncological Outcome in Patients Undergoing Two-Stage Hepatectomy for Colorectal Liver Metastases